AVI BioPharma (AVII) Gets DSMB Has No Concerns for Eteplirsen Phase IIb, Will Continue Trial

AVI BioPharma, Inc. (Nasdaq: AVII), reports the independent Data Safety Monitoring Board (DSMB) providing oversight for AVI's Phase IIb study of eteplirsen in Duchenne Muscular Dystrophy (DMD) patients has reviewed the 12-week biopsy data from the highest dose cohort (50 mg/kg). Following its assessment of this biopsy data, along with other laboratory results and safety outcomes, the DSMB did not identify any safety concerns and determined it was safe to proceed with the trial as planned.

---

Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!

You May Also Be Interested In

• Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
• Bayer, Onyx Pharma (ONXX) Say Nexavar Missed Primary Endpoint in Phase 3
• Baird Reiterates a 'Neutral' on Onyx Pharmaceuticals (ONXX); Nexavar Miss Not Real Issue; Kyprolis Remains Focus

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter